MXCT - MaxCyte, Inc.
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.
ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte's common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte's common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer at MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of August 31, 2026 as an inducement material to entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte's SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).
MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company's $10 million share repurchase program authorized by the Board Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.
ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.
ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
ROCKVILLE, Md. & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder's proprietary MiniVec™ plasmid system and MaxCyte's world-class clinical.
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the decline.
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
MaxCyte, Inc. (NASDAQ: MXCT - Get Free Report) has been assigned a consensus rating of "Hold" from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company.
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit (“RSU”) award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte.
MaxCyte (NASDAQ: MXCT) executives told investors the company made "meaningful progress" in 2025 despite a difficult operating environment, highlighting continued strategic platform license (SPL) activity, integration of the SeQure Dx acquisition, cost restructuring, and the February launch of a new research-focused electroporation system. Management also provided 2026 revenue guidance that reflects ongoing headwinds in the first
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript